Kotak's alternative investment fund pumps in ₹1,070 cr in Biocon. Details here : vimarsana.com

Biocon plans to utilise the proceeds for financing its subsidiary Biocon Biologics' acquisition of the biosimilars business of its partner Viatris to create a global vertically integrated biosimilars player.

Related Keywords

India , Kiran Mazumdar Shaw , Eshwar Karra , Srini Sriniwasan , Shreehas Tambe , Biocon Biologics , Kotak Special Situations Fund , Biocon , Investment Fund , Kotak Investment Advisors , Kotak Investment Advisors Limited , Executive Chairperson , Special Situations Fund , Alternative Investment Fund , Kotak Investment , Kotak Special Situations Fund Biocon Funding , Kotak Special Situations Fund Biocon Investments , Biocon Share Price , Biocon Biologics Viatris Acquisition , Biocon Q3 Result , Biocon Market Cap , Biocon Shares ,